Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors
ConditionMarker; Structural
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age5-50
SponsorCase Comprehensive Cancer Center
About this trial
The purpose of this research study is to investigate whether cancer survivors have higher levels of proteins called Fatty Acid Binding Proteins as well as 12 different markers of cellular senescence than people who have never had cancer. Investigators believe that these levels may be elevated in cancer survivors as a result of their cancer and the treatments they received and may put them at higher risk for chronic conditions such as high cholesterol, diabetes, high blood pressure, and obesity. This study will also compare the levels of these proteins and inflammatory markers in the blood with different aspects of cancer treatment the survivors received. Investigators are investigating if there is a correlation between levels of these proteins and markers, the type of treatment cancer survivors received, and development of metabolic conditions.
Eligibility criteria
Qualifiers
Diagnosis of at least one malignancy for which chemotherapy, radiation, and/or stem cell transplantation was utilized as part of treatment
Completed all therapeutic interventions for their malignancy and are at least 2 years off therapy
At least 1-year post-stem cell transplant for malignant condition
Disqualifiers
Pregnancy at the time of the study
Any autoimmune condition including but not limited to lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis, type 1 diabetes, EXCEPT well-controlled autoimmune hypothyroidism for at least 6 months
Presence of active graft versus host disease
Malignancy treated using surgery only
Trial design
Treatments tested in this trial
- Specimen #1
- Specimen #2
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov